Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings tomorrow afternoon. Here’s what investors should ...

BofA analysts, in a note this month, said Nvidia's results will mark the "next important test for AI bulls," adding that the company's per-share profit "could have enough substance even if less sizzle ...

After a brief and relatively quiet week for earnings, this week promises to bring a wave of significant reports, offering ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) saw unusually-high trading volume on Friday after Bank of America raised their price target on the stock from $18.00 to $21.00. Bank of ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...

UnitedHealth Group is under investigation by the Justice Department **over its Medicare billing prac ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...